Genmab — August 2018
-
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. https://www.ncbi.nlm.nih.gov/pubmed/30080247
-
Hej Raffles og Stroka, Tak for skarpe spørgsmål til Q&A. Alle andre må også meget gerne fyre løs.

-
-
-
-
Ha ha

-
Tre sjæle - en tanke.

-
God morgen.

-
Spørgsmål til Q&A modtages meget gerne.

-
Her er Lundbecks annoncering af det nye studie mod Parkinsons sygdom. Som jeg læser meddelelsen er første deltager indrulleret i "Lu AF82422" http://investor.lundbeck.com/da/news-releases/news-release-details/lundbeck-starter-klinisk-udvikling-af-potentiel-ny-biologisk
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind